Experimental stem cells offered to kids with rare COVID complication
NCT ID NCT04456439
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study provides early access to an experimental stem cell treatment called remestemcel-L for children aged 2 months to 17 years with MIS-C, a severe inflammatory condition linked to COVID-19. The treatment aims to calm the immune system and reduce inflammation. Participants receive up to two infusions of the cells, along with standard medicines to prevent allergic reactions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
remestemcel-L (human mesenchymal stromal cells)
What this could lead to
If successful, this could provide a treatment option for children with severe MIS-C, a rare but serious inflammatory condition linked to COVID-19.
What could go wrong
This is an expanded access program, not a full clinical trial, so results are limited. The number of participants is small, and the therapy may not work for all children or could cause side effects like allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) ASSOCIATED WITH CORONAVIRUS DISEASE (COVID-19) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.